Mount Sinai Medical Center shared a post on LinkedIn:
“After being diagnosed with stage IV ovarian cancer in 2019, Carmen E. Chumaceiro Villasmil has spent nearly seven years under the care of Dr. Brian Slomovitz, Director of Gynecologic Oncology, at Mount Sinai Medical Center. Now, with the recent FDA approval of a new treatment option for platinum-resistant ovarian cancer, patients like Carmen have expanded possibilities when they need them most.
Reflecting on the breakthrough, Carmen shared, ‘Knowing that there are people working to give others a chance at life—it’s everything.’
Ovarian cancer remains one of the most challenging gynecologic cancers to treat, particularly once it becomes resistant to standard platinum-based chemotherapy. This advancement represents an important step forward in gynecologic oncology and opens a new door of hope for patients facing platinum-resistant disease.
At Mount Sinai, innovation and compassionate care continue to work hand in hand to improve outcomes for women with ovarian cancer.”
More posts about Mount Sinai Medical Center.